NICHE-3 Demonstrates Equally Impressive Results as NICHE-2 - Physician's Weekly


Advertisement

NICHE-3 Demonstrates Equally Impressive Results as NICHE-2

Oct 27, 2023

REFERENCES & ADDITIONAL READING

Chalabi M, et al. Ann Oncol. 2022;33(suppl 7):S1389.

 

Amaria RN, et al. Nature 2022;611:155–160.

 

Verschoor YL, et al. Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study. Abstract LBA31, ESMO 2023, 20–24 October, Madrid, Spain.

ABOUT THE CONTRIBUTORS

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

RELEVANT ARTICLES FOR YOU